Ask VialBase
Research

Thymosin Alpha-1 as Immune Adjuvant for COVID-19 Vaccination — VialBase Research

Trial Summary

Phase 1 trial evaluating Thymosin Alpha-1 (Ta1) as an immune adjuvant to enhance COVID-19 vaccine responses. Ta1 is a 28-amino-acid thymic peptide that modulates dendritic cell maturation, T-cell differentiation, and antibody class switching. It has been used clinically for decades (approved in 35+ countries as Zadaxin) for hepatitis B/C and as an immune modulator, but this application as a vaccine adjuvant is newer.

Design

  • Type: Randomized, controlled
  • Population: Adults (likely immunocompromised or elderly poor vaccine responders)
  • Arms: COVID-19 vaccine + Ta1 vs. COVID-19 vaccine alone
  • Duration: 6-12 months with serial immune monitoring
  • Key measures: Anti-spike antibody titers, neutralizing antibody levels, T-cell responses (CD4/CD8 activation, IFN-gamma production), safety/tolerability

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

Ta1 has the longest clinical track record of any immunomodulatory peptide (30+ years, approved in multiple countries). Using it as a vaccine adjuvant is a logical extension of its immune-priming mechanism. If it enhances vaccine responses in poor responders (elderly, immunocompromised), this creates a platform application for Ta1 beyond chronic viral hepatitis. Relevant to thymosin alpha-1 immunology and peptide vaccine adjuvants.

See Also